| |
|
|
|
Seaport World Trade Center, Boston, MA
September 26-27, 2013
Day 1: September 26, 2013 - 2:00 A Special Intraocular Contemplation for New Format Antibody Formulations
- 2:30 Intrinsic Toxicity Pathways Affecting Survival of Ganglion Cells in Injured Retina
- 3:00 Antibody Fragment Pharmacokinetics in the Eye and Implications for Bi-Specific Therapeutics
- 3:30 Breakthrough Solutions for Ocular Diseases
- 4:30 Treating Ocular Disease with Therapeutic Mirror Proteins
- 5:00 Cell-Based Therapies for Ocular Disease
Day 2; September 27, 2013 - 8:30 P529: A First-in-Class Dual Dissociative TORC1/TORC2 Small Molecule Drug Inhibitor of the PI3K Pathway
- 9:00 Bi-Specific Aptamer-Based Antagonists of VEGF and PDGF for the Treatment of Age-Related Macular Degeneration
- 9:30 Antihistimines in Ocular Allergy: The Promise of H1R/H4R Dual-Action Antagonists
- 10:30 Antisense Oligonucleotides: A Close Look at a Topic that Makes Sense
- 11:00 Development of Novel Small Molecule Inhibitors Targeting Atypical PKC to Prevent Retinal Edema
- 11:30 Targeted Nanoparticle Therapy using Intraceptor Inhibition of Choroidal Neovascularization
- 1:50 Lens Epithelium-Derived Growth Factor Fragment (LEDGF1-326), a Novel Therapeutic Protein: Biosynthesis, Characterization, and Efficacy in Retinal Degenerative Diseases
- 2:20 Inhibition of Cytokine Signaling to Treat Ocular Diseases
- 2:50 Treatment for Dry Form AMD in a New Mouse Model
- 3:10 The Many Facets of PEDF in Drug Discovery and Disease: A Diamond in the Rough or Split Personality Disorder?
|
|
|
|
|
|
|
|
Organized by:
|
|
Cambridge Healthtech Institute |
|
|
Invited Speakers:
|
|
- Dhananjay Jere, Ph.D., Group Leader, PTDE, Hoffmann-La Roche
- Val Shestopalov, Ph.D., Associate Professor, Ophthalmology, Bascom Palmer Eye Institute, University of Miami Ophthalmology
- Justin Scheer, Ph.D., Scientist, Protein Chemistry, Genentech, Inc.
- Guillaume Pfefer, President & CEO, Kala Pharmaceuticals
- Dana Ault-Richie, Ph.D., CEO, Reflexion Pharma
- Mohammed El-Kalay, Ph.D., Research and Development, EyeCyte, Inc.
- David Sherris, Ph.D., CEO, Paloma Pharmaceuticals, Inc.
- Nebojsa Janjic, Ph.D., CSO, R&D, SomaLogic, Inc.
- Rogier Smits, Ph.D., Managing Director, Medicinal Chemistry, Griffin Discoveries BV
- Eric Thorin, Ph.D., Chief Development Officer, Gene Signal International, SA
- David A. Antonetti, Ph.D., Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan
- Michael Burr, Ph.D., Research Scientist, Moran Eye Center, University of Utah
- Uday B. Kompella, Ph.D., Director, Kompella Lab, University of Colorado Anschutz Medical Campus
- Eric Furfine, Ph.D., President of R & D, Eleven Biotherapeutics
- Haoyu Mao, Ph.D., Department of Molecular Genetics and Microbiology, University of Florida College of Medicine
- Olga Volpert, Ph.D., Associate Professor, Feinberg School of Medicine at Northwestern University
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
August 16, 2013
|
|
|
|
|
|
|
|
Registration:
|
|
Register Now
|
|
|
E-mail:
|
|
kwaterman@healthtech.com
|
|
|
|
|
|
|
|
|